Premium
O4‐02‐01: PHASE 2A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRM‐0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS
Author(s) -
Boxer Adam L.,
Moebius Hans,
Harris Baruch,
Boeve Bradley F.,
Borroni Barbara,
Swieten John C.,
Grossman Murray,
Pasquier Florence,
Frisoni Giovanni B.,
Mummery Catherine J.,
Vandenberghe Rik,
Le Ber Isabelle,
Hannequin Didier,
McGinnis Scott M.,
Auriacombe Sophie,
Onofrj Marco,
Goodman Ira J.,
Riordan Henry J.,
Wisniewski Gary,
Hesterman Jacob,
Marek Ken,
Patzke Holger,
Koenig Gerhard,
Hilt Dana
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4746
Subject(s) - frontotemporal lobar degeneration , medicine , tolerability , neurodegeneration , asymptomatic , placebo , oncology , frontotemporal dementia , pathology , dementia , disease , adverse effect , alternative medicine